Immunotherapy of Glioblastoma with Metabolically Superior Bi-Specific CAR T-Cells
Grant Amount: NIS 1.75 Million
About the Project
Chimeric antigen receptor (CAR) T-cell therapy of glioblastoma has limited success due, in part, to two issues: Antigen escape through a molecular change and metabolic exhaustion of the CAR T-cells due to nutrient insufficiency in the glioblastoma microenvironment. To overcome these obstacles, the researchers will develop bi-specific and metabolically superior CAR T cells that will target two different molecules, and which will be genetically programmed to overcome glucose and oxygen insufficiency. The study is expected to provide a novel approach and practical tools for precision therapy of glioblastomas, and therefore is crucial for the transitioning of CAR T-cells from a promising treatment – to an effective one. The study is being conducted in cooperation with the Sheba Medical Center.
Research Team
Dr. Michael Berger
The Hebrew University of Jerusalem (Immunology and Cancer Research, School of Medicine)
Dr. Dinorah Friedmann-Morvinski
Tel Aviv University (Biochemistry and Molecular Biology)
More Projects Funded